- RXi Pharmaceuticals (RXII) has outlined its 2018 business strategy at the Biotech Showcase Conference.
- RXi will focus development initiatives on novel immuno-oncology therapeutics using its proprietary sd-rxRNA platform, with a near term focus on Adoptive Cell Transfer. This will reduce quarterly burn-rate for 2018.
- The Company plans to accelerate the development of RXI-762 and RXI-804, sd-rxRNA compounds.
- Expanding research resources, internal development efforts and external collaborations with various existing cell-based approaches.
- Developing immuno-oncology targets beyond checkpoint inhibition, i.e. cell differentiation.
- RXi intends to partner/out-license both its Dermatology and Ophthalmology Franchises. These transactions will provide non-dilutive funding for the Company's focused development path in Immuno-oncology.